Clinical Trial Update: Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell Malignancies [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating anti-CD7 CAR-T cell therapy for relapsed/refractory CD7-positive T-cell malignancies has completed, assessing safety and preliminary ef…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Angioimmunoblastic T-cell Lymphoma
• Peripheral T-cell Lymphoma
• T-cell Acute Lymphoblastic Leukemia
• T-lymphoblastic Leukemia Lymphoma

Drugs mentioned

• Anti-CD7 CAR-T cell therapy (CD7-targeted CAR-T cell therapy)

Snippet

Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Conditions: T Lymphoblastic Leukemia/Lymphoma, T-cell Acute Lymphoblastic Leukemia | Phase 1 | Status: COMPLETED